PT-141 Injection Reviews: What Researchers and Users Report in 2026

PT-141 (bremelanotide) produces measurable improvements in sexual desire and arousal—roughly 34% of men in controlled studies report significantly improved erectile function versus 9% on placebo, and women in FDA trials gained an average of 0.7 additional satisfying sexual events per month versus 0.2 for placebo.[1][2] The trade-off: 40% of users experience nausea, 20% report flushing, and the drug requires subcutaneous injection 45 minutes before sexual activity.[1][3] For researchers sourcing PT-141, pricing runs $219–400 per treatment course from verified peptide suppliers including Marek Health.[8]

PT-141 is FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women; male use remains investigational and off-label.[2][3] The compound works centrally via melanocortin-4 receptor agonism in the hypothalamus, triggering dopamine release that drives sexual motivation—distinct from PDE5 inhibitors that act peripherally on vascular tissue.[4][5] Research protocols evaluating PT-141 in sexual medicine contexts are detailed in clinical guides available through peptide therapy treatment resources.

Clinical Efficacy: What the Data Show

In phase 3 RECONNECT trials, women receiving 1.75 mg bremelanotide subcutaneously showed statistically significant improvements on validated desire scales.[2] The concrete behavioral outcome—a mean increase of 0.7 satisfying sexual events per month (SD 2.4) versus 0.2 for placebo (SD 2.3, p=0.018)—translated into meaningful relationship and quality-of-life gains.[2][7] One early trial found 67% of bremelanotide-treated women reported feelings of sexual desire within 24 hours versus 22% on placebo (p=0.0114).[10]

In men, controlled studies used higher doses (7–20 mg) and found erectile responses sufficient for intercourse occurred significantly more often than placebo, with first erection typically at 30 minutes post-injection.[1] Approximately 34% of treated men achieved significantly improved erectile function compared with only 9% on placebo.[1] A small combination trial with sildenafil demonstrated enhanced response when PT-141 was added in men who had responded inadequately to sildenafil alone, suggesting synergy between central and peripheral mechanisms.[1][9]

Urologists report PT-141 appears most effective in men whose dysfunction has prominent psychogenic or mental components—performance anxiety, stress-related libido issues, or mixed ED with intact basic penile vasculature.[1][6][9] Men considering whether PT-141 compares to a PDE5 inhibitor for their profile can explore options through specialized clinics or state-specific telehealth services.

"For men whose ED is heavily influenced by performance anxiety or psychogenic factors, PT-141 can work even when PDE5 inhibitors have failed. Many men describe it as 'flipping the switch' in the brain that restores desire and facilitates erections."[9]

Dosing and Administration

FDA-approved dosing for women (Vyleesi) is 1.75 mg subcutaneous injection in the abdomen or thigh, administered at least 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and eight doses per month.[2][3][5] For men, no FDA-approved regimen exists; research protocols in clinical settings typically evaluate 500 micrograms to 1 mg subcutaneously to balance observed benefit against nausea incidence.[5][9] Early trials using 7–20 mg produced robust erectile responses but unacceptably high rates of nausea; current clinical research reflects dose optimization learned over time.[1][9] Providers like PeterMD and Hims offer consultations for sexual health treatments.

Onset of noticeable effects occurs within 30–60 minutes of injection, with peak effects within several hours and subjective arousal effects persisting across a 6–8 hour window.[1][2]

Safety Profile and Tolerability

Across trials, 40% of patients experienced nausea, 20% reported flushing, 13% had injection-site reactions, 11% had headache, and 4.8% experienced vomiting.[1][3][6] These adverse effects typically begin soon after injection and resolve within hours.[1][2][6]

"Nausea is typically worst with early doses and may diminish with repeated exposure, but in a substantial minority it remains bothersome and is a major reason for discontinuation."[6]

PT-141 causes small but measurable increases in blood pressure—approximately 6 mmHg systolic and 3 mmHg diastolic, peaking around 4 hours post-injection.[3]

Frequently asked questions

How effective is PT-141 for men with erectile dysfunction?

Approximately 34% of men treated with PT-141 achieved significantly improved erectile function and ability to maintain erections adequate for intercourse, compared with only 9% on placebo in controlled studies. The medication appears most effective in men whose dysfunction has prominent psychogenic, neurogenic, or central components—such as performance anxiety or stress-related libido issues—rather than severe structural vascular disease. First erection typically occurs at 30 minutes post-injection, with effects persisting across a 6–8 hour window.

What are the most common side effects of PT-141 injections?

Nausea is the most common side effect, occurring in 40% of users, followed by flushing in 20%, injection-site reactions in 13%, and headache in 11% of patients. These adverse effects typically begin soon after injection and resolve within hours as drug levels decline, though nausea can be severe enough to prompt discontinuation in some cases. PT-141 also causes small increases in blood pressure—approximately 6 mmHg systolic and 3 mmHg diastolic—peaking around 4 hours post-injection.

How much improvement do women experience with PT-141 for low sexual desire?

Women receiving 1.75 mg bremelanotide subcutaneously showed a mean increase of 0.7 satisfying sexual events per month versus 0.2 for placebo in phase 3 RECONNECT trials. In early trials, 67% of bremelanotide-treated women reported feelings of sexual desire within 24 hours versus 22% on placebo. Women described increased spontaneous sexual thoughts, more frequent initiation, and heightened physical arousal, with some cumulative relational benefits that outlasted acute pharmacologic effects of individual doses.